A Phase 1 Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Mucosal Pemphigus Vulgaris, Sponsored by Cabaletta Bio, Inc.
Learn more about the DesCAARTes™ clinical trial by downloading this brochure
Visit our DesCAARTes™ clinical trial page at ClinicalTrials.gov
Mucosal pemphigus vulgaris (mPV) is an autoimmune disorder in which painful blisters are formed on the inside of the mouth, nose, throat, eyelids, anus, and genitals. In an autoimmune disorder, your body’s own defense system, the immune system, attacks the body by mistake. In mucosal pemphigus vulgaris, B cells – a type of immune cell in your body – mistakenly attack a protein related to skin cells, called desmoglein 3 (DSG3). B cells are important for fighting infections, but “bad” B cells make antibodies that attack DSG3. This causes formation of painful blisters.
Mucosal pemphigus vulgaris can be treated with corticosteroids or immunosuppressant medications. However, these medications suppress the entire immune system. This puts people at risk of serious infections and other side effects. Therefore, new personalized treatment options are needed for people with mucosal pemphigus vulgaris.
A clinical research study is a medical study that helps to answer important questions about an investigational medication or product, such as:
All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.
The DesCAARTes™ study is being done to find the highest dose of an investigational product, autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART), that can safely be given to people with mucosal pemphigus vulgaris. It is sponsored by Cabaletta Bio, Inc. About 30 people with mPV are expected to take part.
The investigational product, DSG3-CAART, will be made from your own T cells. A T cell is a type of white blood cell. White blood cells fight against invaders that enter the body. Your white blood cells, including your T cells, will be collected from your body and your T cells will be changed, or genetically modified, in a laboratory. After the investigational product has been made from your own T cells, it will be returned to you as an infusion through a needle in your vein. The investigational product is designed to change your T cells, so they attack and kill the “bad” B cells in your body that cause pemphigus vulgaris.
You may be able to take part if:
Are you wondering if this clinical trial is right for you? A representative from our patient recruitment center would be glad to discuss the study with you. Alternatively, please email the Cabaletta Study Team.
Patient Recruitment Center Contact Information:
Patient Recruitment Center Contact Information:
Phone: +1-800-711-4906
Email*: cabalettatrials@iqvia.com
Cabaletta Study Team::
Email: clinicaltrials@cabalettabio.com
*Please include only your name and telephone number in the email. Someone from the recruitment center will contact you to discuss the study.